Introducing Sofosbuvir/Velpatasvir + Ribavirin as a Generic Retreatment Regimen for Hepatitis C: Evaluation of a Government Program in Rwanda
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciae637 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Janvier Serumondo und 16 weiteren Autor:innen. Beteiligte Einrichtung: Rwanda Ministry of Health, Rwanda Biomedical Center, Kigali, Rwanda. Hauptthemen laut MEDLINE: Sofosbuvir, Antiviral Agents, Heterocyclic Compounds, 4 or More Rings, Ribavirin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: United Kingdom Federal, Commonwealth & Development Office, SHAPE, Rwandan government.
Abstract (Originalsprache)
Sofosbuvir/velpatasvir/voxilaprevir is recommended for hepatitis C virus (HCV) retreatment in those who fail initial treatment but is unavailable in resource-limited settings. We describe a government sofosbuvir/velpatasvir + ribavirin (SOF/VEL + RBV) × 24 weeks retreatment program in Rwanda (November 2021–October 2022). Of 231 participants, 174 were cured (75.3% intention-to-treat analysis). SOF/VEL + RBV may be considered for HCV retreatment in resource-limited settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rwanda Ministry of Health, Rwanda Biomedical Center, Kigali, Rwanda.
- Clinton Health Access Initiative, Kigali, Rwanda.
- Department of Internal Medicine, The University Teaching Hospital of Kigali, Kigali, Rwanda.
- Clinton Health Access Initiative, Boston, Massachusetts, USA.
ORCID-Profile: Ephrem Daniel Sheferaw, Charles Berabose, Justine Umutesi, Caroline E Boeke, Christian B Ramers
Förderung
- United Kingdom Federal, Commonwealth & Development Office
- SHAPE
- Rwandan government
- Clinton Health Access Initiative
Zitieren
APA
Serumondo, J., Barebwanuwe, P., Sheferaw, E. D., Iyonizera, J., Berabose, C., Umuraza, S., Ntuyenabo, C., Kwizera, K. R., Dushimiyimana, D., Umutesi, J., Kabakambira, J. D., Buya, B., Azania, A., Boeke, C. E., Ngwije, A., Ramers, C. B., & Rwibasira, G. (2025). Introducing Sofosbuvir/Velpatasvir + Ribavirin as a Generic Retreatment Regimen for Hepatitis C: Evaluation of a Government Program in Rwanda. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae637
Vancouver
Serumondo J, Barebwanuwe P, Sheferaw ED, Iyonizera J, Berabose C, Umuraza S, et al. Introducing Sofosbuvir/Velpatasvir + Ribavirin as a Generic Retreatment Regimen for Hepatitis C: Evaluation of a Government Program in Rwanda. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae637
BibTeX
@article{Serumondo2025,
author = {Serumondo, Janvier and Barebwanuwe, Peter and Sheferaw, Ephrem Daniel and Iyonizera, Jeannette and Berabose, Charles and Umuraza, Sabine and Ntuyenabo, Calliope and Kwizera, Kelly Reine and Dushimiyimana, Donatha and Umutesi, Justine and Kabakambira, Jean Damascene and Buya, Bobo and Azania, Amy and Boeke, Caroline E and Ngwije, Alida and Ramers, Christian B and Rwibasira, Gallican},
title = {Introducing Sofosbuvir/Velpatasvir + Ribavirin as a Generic Retreatment Regimen for Hepatitis C: Evaluation of a Government Program in Rwanda},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciae637}
}
EUVIMED